Litcius/Paper detail

A phase 1, single centre, open label, escalating dose study to assess the safety, tolerability and immunogenicity of a therapeutic human papillomavirus (HPV) DNA vaccine (AMV002) for HPV-associated head and neck cancer (HNC)

Janin Chandra, Wai-Ping Woo, Neil Finlayson, Howard Liu, Margaret McGrath, Rahul Ladwa, Michelle Brauer, Yan Xu, Sarah Hanson, Benedict Panizza, Ian H. Frazer, Sandro Porceddu

2020Cancer Immunology Immunotherapy32 citationsDOIOpen Access PDF

Topics & Concepts

TolerabilityMedicineImmunogenicityELISPOTVaccinationAdverse effectAntibodyInternal medicineImmunologyHead and neck cancerVirologyGastroenterologyCancerImmune systemT cellCervical Cancer and HPV ResearchHead and Neck Cancer StudiesImmunotherapy and Immune Responses
A phase 1, single centre, open label, escalating dose study to assess the safety, tolerability and immunogenicity of a therapeutic human papillomavirus (HPV) DNA vaccine (AMV002) for HPV-associated head and neck cancer (HNC) | Litcius